Joint venture expected to utilize Degron’s GlueXplorer platform to identify, validate, and optimize molecular glue degraders.

Sunshine Health is a subsidiary of the Centene Corporation, who has partnered with Cityblock in two other states: New York ...

Approval for the Phase III protocol of LAE002 Plus LAE001 come as a result of posiive Phase II data, which showed promising ...

Under terms of the agreement, Nona Biosciences is expected to receive an upfront payment of $19 million, with the potential ...

Cencora’s associate director of value and access strategy for its commercialization strategy & access solutions division ...

Inizio’s chief operations officer discusses how pharmaceutical companies are tailoring their product launch strategies to ...

In an interview with Pharm Exec Associate Editor Don Tracy, Carmen Villar, VP, ESG & Corporate Citizenship, Gilead Sciences ...

Moving forward, Durect plans on incorporating feedback from the FDA in the design of a Phase III trial.

In an interview with Pharm Exec Associate Editor Don Tracy, Robert Zirkelback, Chief Public Affairs Officer, Head of ...

Spring is in the air, and for many students, graduation is just around the corner. With new grads preparing to start their ...

Approval of Yesafili represents Biocon’s entrance into the US ophthalmology market, following previous approvals in Europe ...